Immunosuppressant Interactions
Transplant immunosuppressants have narrow therapeutic indices and complex metabolic profiles. Drug interactions can cause graft rejection or life-threatening toxicity.
Clinical Stakes
Immunosuppressant drug interactions in transplant patients are among the highest-stakes scenarios in pharmacology. Subtherapeutic levels cause acute rejection and potential graft loss. Supratherapeutic levels cause nephrotoxicity, neurotoxicity, infections, and malignancy. Therapeutic drug monitoring (TDM) is mandatory.
Calcineurin Inhibitors: Cyclosporine and Tacrolimus
Both are CYP3A4 and P-glycoprotein (P-gp) substrates with narrow therapeutic windows.
Dangerous Inhibitors (Increase Levels)
- Azole antifungals — ketoconazole, itraconazole, voriconazole, posaconazole all potently inhibit CYP3A4. Voriconazole increases tacrolimus AUC 3-fold; dose reduction of 60-70% is required.
- Macrolides — clarithromycin and erythromycin; azithromycin is safer
- Calcium channel blockers — diltiazem and verapamil inhibit CYP3A4; sometimes intentionally used to reduce cyclosporine dose and cost
- Grapefruit — variable but clinically relevant for cyclosporine
Dangerous Inducers (Decrease Levels)
- Rifampin — can reduce tacrolimus levels by 80-90%, causing acute rejection within days. If rifampin is essential, dose increases of 3-5 fold and daily TDM are required.
- Phenytoin, carbamazepine, phenobarbital — antiepileptic inducers
- St. John's wort — multiple transplant rejection cases reported; absolutely contraindicated
mTOR Inhibitors: Sirolimus and Everolimus
Also CYP3A4 and P-gp substrates. Same inhibitors and inducers apply. Additional concern: sirolimus combined with cyclosporine synergistically increases nephrotoxicity and should be separated by at least 4 hours if used together.
Mycophenolate
Mycophenolate mofetil (MMF) is hydrolyzed to mycophenolic acid (MPA), which undergoes glucuronidation and enterohepatic recirculation. Key interactions:
- Cyclosporine — inhibits MPA enterohepatic recirculation, reducing MPA levels by 30-40%. Switching from cyclosporine to tacrolimus increases MPA exposure.
- Proton pump inhibitors — may reduce MMF absorption (likely clinically insignificant with enteric-coated mycophenolate sodium)
- Cholestyramine — binds MPA in the gut, significantly reducing levels; contraindicated in combination
- Acyclovir/valacyclovir — competes with MPA for renal tubular secretion; both drug levels may increase
Practical Management
| Scenario | Action |
|---|---|
| Starting azole antifungal | Reduce CNI dose 50-70%, check level in 2-3 days |
| Starting rifampin | Increase CNI dose 3-5x, daily TDM |
| Switching cyclosporine to tacrolimus | Monitor MPA levels; may need MMF dose reduction |
| New antiepileptic | Choose levetiracetam (no CYP interaction) over carbamazepine/phenytoin |
Key Takeaways
- Calcineurin inhibitors and mTOR inhibitors are CYP3A4/P-gp substrates with narrow therapeutic indices
- Azole antifungals and rifampin are the most impactful interacting drugs in transplant care
- Rifampin can reduce tacrolimus levels by 80-90% and should be avoided if possible
- Switching between cyclosporine and tacrolimus alters mycophenolate exposure
- Levetiracetam is the preferred antiepileptic in transplant patients due to lack of CYP interactions